Schering-Plough Pads Late-Stage Pipeline with $14B Acquisition of ...

Mar 12, 2007 · Schering-Plough will acquire Organon BioSciences, the human and animal health care businesses of Akzo Nobel, for approximately Euro 11 billion in cash, or about $14.4 billion.

CouponFollow Extension

$14
OFF

Schering-Plough Pads Late-Stage Pipeline With $14B Acquisition Of ...

3 weeks from now

Mar 12, 2007 · Schering-Plough will acquire Organon BioSciences, the human and animal health care businesses of Akzo Nobel, for approximately Euro 11 billion in cash, or about $14.4 billion.

genengnews.com

$14
OFF

Schering-Plough Pays $14.4B For Organon - Fierce Biotech

3 weeks from now

Mar 11, 2007 · Akzo Nobel has canceled plans to take its drug unit Organon public and snatched up a 37 percent premium for the operation in a deal to sell the company to Schering-Plough for …

fiercebiotech.com

$14
OFF

Schering-Plough Buys Akzo's Organon For $14.5 Billion - CNBC

3 weeks from now

Mar 12, 2007 · Akzo Nobel said on Monday it was selling its drugs unit Organon BioSciences to Schering-Plough for 11 billion euros ($14.5 billion), dropping plans to float it in a public share …

cnbc.com

$7
OFF

Chemical Industry News And Analysis - Chemistry World

3 weeks from now

News and analysis from across the chemical sciences. The latest on pharmaceutical, agrichemical, fine and speciality chemical and petrochemical industries. ... $7.4 billion proposal ...

chemistryworld.com

$14
OFF

Schering-Plough Offers $14 Billion For Organon

3 weeks from now

The Schering-Plough offer exceeds both Akzo's $9 billion estimate of proceeds from a stock market launch and analysts' recent estimates that a buyer might pay about $10 billion for the …

acs.org

$7
OFF

Chemistry News, Research And Opinions | Chemistry World

3 weeks from now

Chemistry, covered. Science news, research, reviews, features and opinions. Read Chemistry World to keep up with stories from across the chemical sciences. ... $7.4 billion proposal ...

chemistryworld.com

4%
OFF

Investors Heavily Search Organon & Co. (OGN): Here Is What You …

3 weeks from now

Nov 4, 2024 · For the current quarter, Organon is expected to post earnings of $0.98 per share, indicating a change of +11.4% from the year-ago quarter. The Zacks Consensus Estimate has …

yahoo.com

40%
OFF

Organon's Valuation Is Not Expensive - Yahoo Finance

3 weeks from now

Mar 5, 2024 · Organon's revenue for the fourth quarter of 2023 was about $1.6 billion, exceeding our expectations by about $80 million and, importantly, growing 7.40% year over year. Story …

yahoo.com

$3
OFF

Organon's SWOT Analysis: Stock Poised For Growth Amid Challenges

3 weeks from now

Dec 18, 2024 · The company's market capitalization currently stands at $3.8 billion, with notable financial metrics including an attractive P/E ratio of 2.9x and a substantial dividend yield of …

investing.com

$9
OFF

As Organon Charts Post-spinoff Future, Merck's $9B Cash Infusion …

3 weeks from now

May 4, 2021 · Merck will score $9 billion from the spinoff, and the company plans to scout for business development deals with that new funding, incoming CEO Rob Davis said at an …

fiercepharma.com

56%
OFF

Here's Why Organon (OGN) Gained But Lagged The Market Today

3 weeks from now

Oct 14, 2024 · In the latest trading session, Organon (OGN) closed at $18.10, marking a +0.56% move from the previous day. This move lagged the S&P 500's daily gain of 0.77%. Elsewhere, …

nasdaq.com

12%
OFF

Organon: What’s Next For The New Merck & Co. Spin-off?

3 weeks from now

Aug 18, 2021 · The new company consists of approximately 9,000 employees, which represented 12% of Merck’s global workforce as of December 31, 2020. In its second-quarter 2021 …

dcatvci.org

$3
OFF

Organon's SWOT Analysis: Stock Poised For Growth Amid Challenges

3 weeks from now

Dec 18, 2024 · The company's market capitalization currently stands at $3.8 billion, with notable financial metrics including an attractive P/E ratio of 2.9x and a substantial dividend yield of …

investing.com

$1
OFF

Billion-dollar Deals Bolster Oncology Research - Nature

3 weeks from now

Sep 2, 2024 · Between July 2023 and July 2024, all of the top ten highest-value deals made to target oncology indications were worth over $1 billion, with the largest involving a huge $22 …

nature.com

FAQs about Schering-Plough Pads Late-Stage Pipeline with $14B Acquisition of ... Coupon?

Will Organon's acquisition fill a gap in the drug pipeline?

Schering says that the acquisition will fill a gap in its late stage pipeline and provide immediate access to central nervous system and women’s health care products. The most high profile of Organon’s drugs is the antipsychotic asenapine, tentatively slated for launch later this year. ...

Is Organon a Merck Company?

The name Organon has been a part of Merck since Merck’s acquisition of Schering-Plough in 2009. In 2007, Schering-Plough acquired Organon BioSciences from the Dutch chemical company, AkzoNobel. At the time of the 2007 acquisition, Organon Bioscienes comprised primarily of Organon, a human health business, and Intervet, an animal health business. ...

What is the consensus earnings estimate for Organon?

The consensus earnings estimate of $4.22 for the current fiscal year indicates a year-over-year change of +1.9%. This estimate has changed -2.4% over the last 30 days. For the next fiscal year, the consensus earnings estimate of $4.39 indicates a change of +4% from what Organon is expected to report a year ago. ...

Is Organon a standalone company?

The drugmaker unveiled plans to establish the standalone company a year ago, and, this week, it revealed more about the vision for Organon and its business model. ...

Is Organon a good stock to buy now?

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Organon. Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. ...

Will Organon's spinoff boost sales?

None of the medicines will account for more than 11% of Organon’s revenue. The spinoff will allow both companies to focus more clearly on their respective missions, Davis said. Organon is an "important new company" with a "compelling portfolio" and a "mission in women's health," he said. The spinoff will look to boost sales after years of declines. ...